Paul Blanchart studied Pharmacy at the University of Lille (France) and completed his PharmD in 2026 with a specialization in Research and Industry. Alongside his pharmacy studies, he obtained a Master’s degree with distinction in 2025.

During his academic training, he gained research experience through several internships in both academia and industry, including placements at the U1177 laboratory and the UMR-S 1172 unit in France, as well as at AstraZeneca in Sweden. His research has included PROTACs targeting insulin-degrading enzyme, tryptolines as potential antimalarial compounds, phosphinamides as a functional group in medicinal chemistry, and the synthesis of allosteric ERAP1 inhibitors.

Since October 2024, he has been a PhD candidate in a joint project between the U1177 laboratory and the Department of Drug Design and Optimization under the supervision of Prof. Dr. Rebecca Deprez-Poulain (University of Lille) and Prof. Anna K. H. Hirsch. His work focuses on the use of kinetic target-guided synthesis to investigate atypical binding sites, particularly allosteric sites of ERAP1 and protein-protein interactions involving the DnaN protein.